MK-571 sodium

TargetMol
Product Code: TAR-T3148
Supplier: TargetMol
CodeSizePrice
TAR-T3148-5mg5mg£108.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3148-1mL1 mL * 10 mM (in DMSO)£121.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3148-10mg10mg£132.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3148-25mg25mg£213.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3148-50mg50mg£325.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3148-100mg100mg£450.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
MK-571 is a selective, orally active antagonist of the CysLT1 receptor. MK571 is a multidrug resistance protein-2 (ABCC2, Mrp2) inhibitor used to demonstrate the role of Mrp2 in the cellular efflux of drugs, xenobiotics, and their conjugates. MK571 can inhibit the synthesis of K-4?-O-GlcA (19.7 μM). MK571 dose-dependently inhibits the intracellular biosynthesis of all flavonol sulphates and glucuronides by Caco-2 cells. MK571 significantly inhibits phase-2 conjugation of kaempferol by cell-free extracts of Caco-2, and production of kaempferol-4?-O-glucuronide was competitively inhibited. In addition to inhibiting MRP2, MK571 is a potent inhibitor of enterocyte phase-2 conjugation.
CAS:
115103-85-0
Formula:
C26H26ClN2NaO3S2
Molecular Weight:
537.06
Pathway:
GPCR/G Protein; Immunology/Inflammation
Purity:
0.9869
SMILES:
[Na+].CN(C)C(=O)CCSC(SCCC([O-])=O)c1cccc(C=Cc2ccc3ccc(Cl)cc3n2)c1
Target:
Leukotriene Receptor; LTR

References

1. Jones TR, et al. Can J Physiol Pharmacol. 1989, 67(1):17-28. 2. Amanda Tivnan, et al. Front Neurosci. 2015, 9:218. 3. Depr? M, et al. Eur J Clin Pharmacol. 1992, 43(4):427-30. 4. Luo FR, et al. Drug Metab Dispos. 2002, 30(7):763-70.